Needham & Company Downgrades Hologic (HOLX) to Hold

Go back to Needham & Company Downgrades Hologic (HOLX) to Hold

Hologic (HOLX) Tops Q2 EPS by 1c; Bumps Outlook

April 27, 2016 4:14 PM EDT

Hologic (NASDAQ: HOLX) reported Q2 EPS of $0.47, $0.01 better than the analyst estimate of $0.46. Revenue for the quarter came in at $693.3 million versus the consensus estimate of $687.41 million.

"We posted another good quarter, highlighted by 14.6% growth in non-GAAP EPS," said Steve MacMillan, the Company's... More